ImCheck Therapeutics was founded in 2015 as a spin-off from the Paoli-Calmettes Cancer Institute in Marseille (France). The biotech company is developing innovative antibody therapeutics in the field of immuno-oncology, based on scientific assets originating from the pioneering work of Prof. Daniel Olive.
ImCheck Therapeutics is an emerging player in the field of cancer and auto-immune immunotherapies that focuses on the development of first-in-class antibodies that activate the immune system against different cancer types. Gimv strongly believes in the company because of the game-changing potential of ImCheck’s development candidates for the treatment of cancer.
The funds will be used to advance its lead candidates towards clinical development, as well as to progress its discovery programs.
Our previous investments in Topas Therapeutics, G-Therapeutics, Endostim, Spineart and Breath Therapeutics will allow us to help ImCheck Therapeutics in realizing its ambitions.